BR
Biomedical Reports
2049-9434
2049-9442
D.A. Spandidos
10.3892/br.2019.1249
BR-0-0-1249
Corrigendum
Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors (Review)
UmeneKiyoko
BannoKouji
KisuIori
YanokuraMegumi
NogamiYuya
TsujiKosuke
MasudaKenta
UekiArisa
KobayashiYusuke
YamagamiWataru
NomuraHiroyuki
TominagaEiichiro
SusumuNobuyuki
AokiDaisuke
12
2019
01
11
2019
11
6
274
274
Copyright: © Umene et al.
2019
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
Biomed Rep 1:335-340, 2013; DOI: 10.3892/br.2013.91
Subsequently to the publication of the above review article, the authors have realized that they made an error in terms of the description of the Aurora kinase inhibitor, ZM44739. Concerning the sentence in the section ‘3. Clinical applications of Aurora kinase inhibitors’, on p. 337, right-hand column, lines 7-8, the authors wrote ‘ZM447439 was reported as the first Aurora kinase inhibitor in 2003 and is currently in phase I clinical trials…’; however, a phase I clinical trial with this drug has not yet been conducted. Therefore, this sentence should be corrected to the following: ‘ZM447439 was reported as the first Aurora kinase inhibitor in 2003’.
The authors apologize to the readership of the Journal for the misinformation in this regard, and for any inconvenience caused.